In today’s briefing:
- Samsung Electronics (005930 KS): 2x Leveraged ETF Investors Exit into the August Rally
- Why Samsung Electronics Should Buyback and Cancel At Least 10% of Its Preferred Shares
- Samsung Electronics (005930 KS) Tactical UPDATE Post-9% Monday Sell-Off
- Samsung’s Remaining Return Mix and Two Yearend Trades
- Neopharm Co Ltd (092730 KS): Synthetic Expert Call Transcript (24 Aug 2026)
- Elice Group IPO Preview
- Coupang’s 24.7 Million Customer Engine: Is The Post-Incident Recovery Finally Taking Hold?
Samsung Electronics (005930 KS): 2x Leveraged ETF Investors Exit into the August Rally
- Samsung Electronics (005930 KS) gained 7.2% in August MTD, but combined 2x leveraged ETF AUM fell 3.2% to KRW 3.1tn.
- Cumulative net outflows reached KRW 534bn MTD, with all leveraged ETFs recording reductions in units outstanding.
- Despite Samsung Electronics falling 8.3% since launch, the 2x inverse ETF has lost 56.4%, reducing its AUM to approximately KRW 15bn.
Why Samsung Electronics Should Buyback and Cancel At Least 10% of Its Preferred Shares
- In this insight, I argue why Samsung Electronics should buyback and cancel at least 10% of its preferred shares.
- Clearly, many shareholders have been disappointed with lack of buybacks/cancellations with the recent 30 trillion won dividend program.
- In order to appease many disappointed investors in Samsung Electronics, the company should significantly increase the buybacks/cancellation portion of the remaining shareholder returns, especially for the preferred shares.
Samsung Electronics (005930 KS) Tactical UPDATE Post-9% Monday Sell-Off
- This is a brief update to our recent Samsung Electronics (005930 KS) insight posted last week.
- The stock closed last week up, second week up in a row and extremely high profit target reached (short-term): our models flashed a overbought/sell signal.
- On Monday Samsung Electronics fell -9%. This insight contains the updated SUPPORT MODEL to determine where to buy again the stock.
Samsung’s Remaining Return Mix and Two Yearend Trades
- Samsung’s remaining KRW 70 to 80tn return package looks set at KRW 60tn dividends and KRW 10 to 20tn buybacks, with KRW 40tn a hard dividend floor and potential upside.
- Samsung’s KRW 10 to 20tn buyback could skew heavily toward prefs due to Samsung Life’s 10% constraint, implying potentially 6.7% prefs cancellation versus 0.7% common.
- Samsung offers two yearend trades: pref discount compression with 6.8% yield versus 5.1% common, and dividend arb with 3.3% yield, potentially higher amid continued memory sector vol.
Neopharm Co Ltd (092730 KS): Synthetic Expert Call Transcript (24 Aug 2026)
- The legacy domestic growth engine has hit a structural ceiling. The tightening of private medical indemnity insurance (silbi) reimbursement rules in South Korea has severely constrained the high-margin hospital-exclusive Zeroid MD channel. The transition of the Zeroid brand into mass-retail channels like Olive Young in late 2024 was an essential defense mechanism but is diluting profitability due to intense competition and heavy marketing requirements.
- Operating margins remain healthy but are increasingly vulnerable to K-beauty’s structural inflation of customer acquisition costs (CAC). While Neopharm reported a solid 21.77% operating margin for FY 2025, domestic marketing expenses and slotting fees demanded by the dominant multi-brand store (MBS) channel, Olive Young, are compressing margins.
- Inorganic growth through M&A is urgently required to deploy cash and fill critical portfolio gaps. Despite holding 145.94 billion KRW in net cash with zero debt as of late 2025, management has been overly conservative. A capital allocation policy that prioritizes a 33% to 35% dividend payout ratio over aggressive, strategic acquisitions prevents the company from acquiring active ingredient-led brands (e.g., PDRN, Retinol) or international distribution infrastructure necessary to break the legacy brand ceiling.
Disclaimer: The following transcripts are synthetic, AI-generated on demand, and compiled exclusively from public data sources; no real-word experts were actually interviewed. This content is designed to highlight potential market mispricings, explore compelling lines of inquiry, and suggest strategic questions rather than present verified facts. All specific financial metrics and data points, including market shares, TAM, margins, and growth rates, are AI-estimated approximations. They may be inaccurate and must be independently verified.
Elice Group IPO Preview
- Elice Group is getting ready to complete its IPO on KOSDAQ in September. This is one of the largest IPOs in KOSDAQ this year.
- The IPO price range is from 70,400 won to 90,500 won. The total offering amount is expected to be between 156.4 billion won and 201.1 billion won.
- Elice Group provides full-stack AI solutions based on its proprietary AI cloud technology. Its core business is divided into AI Transformation (AX) and AI Cloud services.
Coupang’s 24.7 Million Customer Engine: Is The Post-Incident Recovery Finally Taking Hold?
- Coupang’s second-quarter 2026 results reflect a complex recovery phase following a disruptive data incident that affected customer behavior and financial performance.
- Consolidated revenue grew by 10% year-over-year on a constant currency basis, marking an improvement from the previous quarter and aligning with prior guidance.
- Product Commerce revenue grew 8% on a constant currency basis, with active customers increasing to 24.7 million, driven by returning higher-spending customers and new customer additions.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
